Cargando…

Third booster vaccination and stopping the Omicron, a new variant of concern

The SARS-CoV-2 omicron variant is recent member of variant of concerns that confer neutralizing antibodies and escape immune system due to harboring more than 40 mutations. Current evidences suggest two dosages SARS-CoV-2 vaccine dose not efficient protects against new variants of SARS-CoV-2; howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghazvini, Kiarash, Karbalaei, Mohsen, Keikha, Masoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259195/
https://www.ncbi.nlm.nih.gov/pubmed/35818430
http://dx.doi.org/10.1016/j.vacun.2022.05.005
_version_ 1784741721374982144
author Ghazvini, Kiarash
Karbalaei, Mohsen
Keikha, Masoud
author_facet Ghazvini, Kiarash
Karbalaei, Mohsen
Keikha, Masoud
author_sort Ghazvini, Kiarash
collection PubMed
description The SARS-CoV-2 omicron variant is recent member of variant of concerns that confer neutralizing antibodies and escape immune system due to harboring more than 40 mutations. Current evidences suggest two dosages SARS-CoV-2 vaccine dose not efficient protects against new variants of SARS-CoV-2; however, recent studies declare that the third booster vaccination can elicit higher antibodies concentration as well as cross-reaction between neutralizing antibodies and new SARS-CoV-2 variants. On the other hand, although a third booster vaccination seems to be benefit in some immunocompromised patients such as recipients of solid-organ transplants or hemodialysis patients, but in other immunosuppressed patients, for instance patients with B cell lymphoproliferative disease partially respond to SARS-CoV-2. Herein, we evaluate the effectiveness of the third booster vaccination against Omicron variant using comprehensive literature review.
format Online
Article
Text
id pubmed-9259195
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-92591952022-07-07 Third booster vaccination and stopping the Omicron, a new variant of concern Ghazvini, Kiarash Karbalaei, Mohsen Keikha, Masoud Vacunas Review Article The SARS-CoV-2 omicron variant is recent member of variant of concerns that confer neutralizing antibodies and escape immune system due to harboring more than 40 mutations. Current evidences suggest two dosages SARS-CoV-2 vaccine dose not efficient protects against new variants of SARS-CoV-2; however, recent studies declare that the third booster vaccination can elicit higher antibodies concentration as well as cross-reaction between neutralizing antibodies and new SARS-CoV-2 variants. On the other hand, although a third booster vaccination seems to be benefit in some immunocompromised patients such as recipients of solid-organ transplants or hemodialysis patients, but in other immunosuppressed patients, for instance patients with B cell lymphoproliferative disease partially respond to SARS-CoV-2. Herein, we evaluate the effectiveness of the third booster vaccination against Omicron variant using comprehensive literature review. Elsevier España, S.L.U. 2022 2022-07-07 /pmc/articles/PMC9259195/ /pubmed/35818430 http://dx.doi.org/10.1016/j.vacun.2022.05.005 Text en © 2022 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Ghazvini, Kiarash
Karbalaei, Mohsen
Keikha, Masoud
Third booster vaccination and stopping the Omicron, a new variant of concern
title Third booster vaccination and stopping the Omicron, a new variant of concern
title_full Third booster vaccination and stopping the Omicron, a new variant of concern
title_fullStr Third booster vaccination and stopping the Omicron, a new variant of concern
title_full_unstemmed Third booster vaccination and stopping the Omicron, a new variant of concern
title_short Third booster vaccination and stopping the Omicron, a new variant of concern
title_sort third booster vaccination and stopping the omicron, a new variant of concern
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259195/
https://www.ncbi.nlm.nih.gov/pubmed/35818430
http://dx.doi.org/10.1016/j.vacun.2022.05.005
work_keys_str_mv AT ghazvinikiarash thirdboostervaccinationandstoppingtheomicronanewvariantofconcern
AT karbalaeimohsen thirdboostervaccinationandstoppingtheomicronanewvariantofconcern
AT keikhamasoud thirdboostervaccinationandstoppingtheomicronanewvariantofconcern